Aprea AB

Aprea AB is a Swedish biotech company based on research performed at Karolinska Institutet, Stockholm, Sweden. The company focuses its activities on discovery and development of novel anticancer compounds targeting the tumor suppressor protein p53. Aberrations in p53 are common in many various cancer forms and are associated with increased resistance to standard chemotherapy and thus poor prognosis. Aprea’s first Investigational Product, APR-246, has recently been tested in a Phase I/II dose escalating safety study in patients with refractory hematological malignancies or prostate carcinoma. The main owners of the company are Karolinska Development, Industrifonden, Östersjöstiftelsen (The Foundation for Baltic and East European Studies) and Praktikerinvest.